Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Individual Comparisons by Ranking Methods

1945 • 12,649 citations

Cancer Statistics, 2005

2005 • 5,487 citations

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 • 5,439 citations

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2004 • 3,606 citations

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

2002 • 1,655 citations

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

1999 • 994 citations

Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

2003 • 674 citations

Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

2000 • 627 citations

Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration

2002 • 388 citations

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

2000 • 260 citations

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

2000 • 189 citations

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

2004 • 187 citations